News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elan Corporation PLC (ELN) Board Rejects Royalty Pharma Takeover Bid


4/22/2013 8:27:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The board of directors of Elan Corp. (ELN) Monday unanimously rejected a takeover bid by Royalty Pharma, a knockback in the U.S. investment firm's two-month-old pursuit of the Irish biotechnology company. Elan's board said the $11.25-a-share bid substantially undervalued the company. "The offer from Royalty Pharma grossly undervalues Elan's current business platform and our future prospects," Elan Chairman Robert A. Ingram said in a statement. The rejection is the latest in an ongoing skirmish between the Dublin-based biotech company and Royalty Pharma, a New York-based intellectual property investor.

Help employers find you! Check out all the jobs and post your resume.

Read at Fox News
Read at Bloomberg
Read at Independent
Read at Irish Times
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES